{
    "root": "35d13593-172f-3a08-e063-6294a90a72fe",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valproic",
    "value": "20250523",
    "ingredients": [
        {
            "name": "PEANUT OIL",
            "code": "5TL50QU0W4"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "VALPROIC ACID",
            "code": "614OI1Z5WI"
        }
    ],
    "indications": "Valproic Acid is an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 )",
    "contraindications": "Valproic Acid is intended for oral administration. ( 2.1 ) Simple and Complex Absence Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/week until seizure control or limiting side effects ( 2.1 ) Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 )",
    "warningsAndPrecautions": "Valproic Acid Capsules, USP, 250 mg. Each off-white colored soft gelatin capsule is imprinted with VALPROIC 250 and made available in bottles of 100 capsules (\n \n  NDC0591-4012-01).\n\n \n                  Store capsules at controlled room temperature 15° to 30°C (59° to 86°F), see USP. Dispense in tight, light-resistant container.",
    "adverseReactions": "Valproic Acid should not be administered to patients with hepatic disease or significant hepatic dysfunction\n  \n   [\n                        see Warnings and Precautions (\n                        \n                           5.1\n                        \n                        )\n                        ]. \n   \n                     \n                     Valproic Acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder\n  \n   [\n                        see Warnings and Precautions (\n                        \n                           5.1\n                        \n                        )\n                        ].  \n   \n                     \n                     Valproic Acid is contraindicated in patients with known hypersensitivity to the drug\n  \n   [\n                        see Warnings and Precautions (\n                        \n                           5.12\n                        \n                        )\n                        ]. \n   \n                     \n                     Valproic Acid is contraindicated in patients with known urea cycle disorders\n  \n   [\n                        see Warnings and Precautions (\n                        \n                           5.6\n                        \n                        )\n                        ].\n                     \n                     For use in prophylaxis of migraine headaches: Valproic Acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception\n  \n   \n                           \n                              \n                                 \n                                    [see Warning and Precautions (\n       \n        5.2,\n       \n        5.3,\n       \n        5.4) and Use in Specific Populations (\n       \n        8.1)]."
}